Inactive Instrument

Press Releases Novozymes A/S Other OTC

Equities

Trading by management and close relations of management	05-17	GL
Trading by management and close relations of management	05-08	GL
Q1 update: Novonesis delivers 4% organic sales growth in line with expectations and reports progress on the integration	05-03	GL
Trading statement Q1 2024	05-03	GL
Novonesis A/S : Resolutions from the annual shareholders' meeting 2024	04-30	PU
Resolutions from the annual shareholders’ meeting 2024	04-30	GL
Novonesis A/S : Invitation to the annual shareholders' meeting	04-08	PU
Invitation to the annual shareholders’ meeting	04-08	GL
Share-based legacy RSU program granted	04-08	GL
2024 outlook and pro forma financials	03-21	GL
2024 outlook and pro forma financials	03-21	AQ
Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21	03-18	GL
Novonesis A/S : Resolutions from the Extraordinary Shareholders' Meeting 2024	03-04	PU
Resolutions from the Extraordinary Shareholders’ Meeting 2024	03-04	GL
Invitation to an extraordinary shareholders’ meeting of Novozymes A/S	02-09	GL
The Novozymes Report 2023	02-08	GL
Trading by management and close relations of management	02-02	GL
Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed	02-02	GL
Legacy Novozymes delivers solid last full-year results	02-01	GL
Results update for 2023 – unaudited	02-01	GL

No results for this search

NOVONESIS : Key segments outperform in average Q1 24 showing

May 10, 2024 at 05:32 pm